logo-loader
viewNetscientific PLC

NetScientific surges as portfolio firm PDS unveils positive data from HPV treatment

PDS said 60% of patients in a Phase 1 trial had responded to PDS0101, which is aiming to treat high-risk, cancer-causing types of HPV

Netscientific PLC - NetScientific eyes further value from investment portfolio in second half

NetScientific PLC (LON:NSCI) shares bounced higher on Thursday after its portfolio firm, PDS Biotechnology, announced positive data from a Phase 1 trial of a treatment for human papillomavirus (HPV).

In the announcement, PDS said 60% of patients in the trial had demonstrated a clinical response to its PDS0101 treatment, which is aiming to treat patients suffering from high-risk, cancer-causing types of HPV.

The plan now is for PDS to initiate three Phase 2 studies for PDS0101, which are due to start in the first quarter of next year.

"We are delighted to see this additional data which further validates the potential of this new treatment for patients suffering with high-risk HPV”, said Ian Postlethwaite, NetScientific’s chief executive.

“We believe that the continued strong progress of the PDS immunotherapy portfolio and NetScientific's shareholding within demonstrates the potential of increasing value for our shareholders as we seek to realise full value of our investments in the coming months."

Targeting more value from portfolio

The news from PDS followed NetScientific saying it was aiming to realise more value from its investment companies in the second half of its financial year.

As part of its results for the six months ending 30 June, the healthcare commercialisation firm said the companies in its portfolio had made “good progress” in the period and that its focus in the second half would be on continuing to increase their value “in an orderly manner”.

READ: NetScientific PLC portfolio company PDS Biotech agrees deal to raise up to US$20mln

“Our portfolio companies continued to make strong progress during the period and we believe they have great potential to create value for our shareholders”, Postlethwaite said.

For the first half, the company reported a loss from continuing operations of £2.1mln, unchanged from the prior year, while revenues rose to £158,000 from £86,000.

The total loss after tax was £7.6mln, compared to a £4.6mln in 2018, reflecting a loss form the disposal of two of the group’s investments, Vortex and Wanda.

Cash resources at the end of the six months stood at £2.5mln compared to £6.9mln a year ago, which the company said was sufficient for it to operate until the end of September 2020.

In mid-afternoon trading on Thursday, NetScientific's shares were 12.5% higher at 7p.

--Adds PDS announcement and updates share price--

Quick facts: Netscientific PLC

Price: 6.18 GBX

AIM:NSCI
Market: AIM
Market Cap: £4.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read